Trials / Completed
CompletedNCT00499538
Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects
A Single Dose Bioavailability Study of 3 New Formulations of SKI-606 (500 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the comparative bioavailability of 3 new tablet formulations of SKI-606 with a reference capsule and an oral solution in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKI-606 |
Timeline
- Start date
- 2007-07-01
- Completion
- 2007-09-01
- First posted
- 2007-07-11
- Last updated
- 2007-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00499538. Inclusion in this directory is not an endorsement.